NCT06943820 - AK129 Combination Therapy for Advanced Solid Tumors | Biotech Hunter

Enrollment

230

Participants

Timeline

Start Date

May 21, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

May 31, 2028

Conditions

Non-small Cell Lung Cancer Stage IIIB/IVHead and Neck Squamous Cell Carcinoma (HNSCC)Colorectal AdenocarcinomaAdvanced Solid Tumors

Interventions

DRUG

AK129(dose 1)

IV infusion

DRUG

Pemetrexed

IV infusion;500mg/m2

DRUG

Paclitaxel

IV infusion;175mg/m2

DRUG

Carboplatin

IV infusion;AUC 5

DRUG

AK129(dose 2)

IV infusion

DRUG

Docetaxel

IV infusion;75mg/m2

DRUG

Cis-platinum

IV infusion;100 mg/m2

DRUG

5-FU (5-fluorouracil)

IV infusion;1000 mg/m2

DRUG

Cetuximab

IV infusion;400mg/m2/ 250mg/m2

DRUG

Paclitaxel

IV infusion;80mg/m2

DRUG

Docetaxel

IV infusion;35mg/m2

DRUG

Chemotherapy

IV infusion

DRUG

AK129(RP2D)

IV infusion

DRUG

Penpulimab

IV infusion;200mg

Trial Locations (1)

110801

RECRUITING

Liaoning Cancer Hospital, Shenyang